IJR News — today's news from every side

IJR News — today's news from every side

blockversewordysbillionaire.aiyourlistWhiteboardAppquizieunschool

Loading

Genius — OpenServe

Want your own hosted, self-optimizing clone of this — or any OpenServe site? Open Development for enterprise →

OpenServe Drive OpenServe Inbox OpenServe Write OpenServe Studio OpenServe Projects OpenServe Focus OpenServe Mindmaps Teams OpenServe CRM Site Builder Whiteboard

© OpenServe Holdings LLC

Privacy Notice Data rights Terms of Service Feedback Cookie NoticeHelp Acceptable Use Copyright AI Notice Your Privacy Choices Subprocessors Data Processing Addendum Installed App Terms Company Solutions Free assessment Investors Get the app Contact

News

Home
Popular
Elections

Genius — OpenServe

Alpha DaRT Pembrolizumab Combo Shows 100% ResponseHealth — Jul 21, 2026Alpha Tau Medical reported positive data from a single-center study of Alpha DaRT combined with pembrolizumab in elderly patients with locally advanced or metastatic head and neck cancer, achieving a 100% systemic objective response rate and an 18.2-month median overall survival with no serious Alpha DaRT-related adverse events. The results, presented at the AHNS conference in Boston, exceeded historical pembrolizumab benchmarks and support continued trials and the company’s strategic push in immuno-oncology, with analyst notes highlighting a Buy rating for DRTS.

0

Ivonescimab Cuts Death Risk 27% in NSCLC TrialHealth — Sep 13, 2026Ivonescimab significantly extends overall survival versus pembrolizumab in first-line PD-L1-positive advanced NSCLC, with a median OS of 30.8 months versus 22.6 months and a 27% reduction in death risk (HR 0.73). Benefits persisted across key subgroups, including PD-L1 high and squamous disease, and are driving international expansion through the ongoing HARMONi-7 study.

0

AIM ImmunoTech Secures Europe UK Ampligen PatentBusiness — Aug 31, 2026AIM ImmunoTech won European and UK patent protection for Ampligen’s use in treating Long COVID, with exclusivity through 2041, adding to a growing global IP position around Ampligen. Separately, the U.S. patent office granted Ampligen protection through 2039 for use with pembrolizumab across multiple cancers, reinforcing AIM's oncology strategy and expanding patent coverage in Europe, Japan, and beyond.

0

Cipla and Qilu ink exclusive deal to sell Keytruda biosimilar in US — Sep 3, 2026Invagen Pharmaceuticals has signed an exclusive US licensing deal with Qilu Pharmaceutical to commercialize QL2107, a Keytruda (pembrolizumab) biosimilar, with Qilu handling development, regulatory work, and supply while Cipla USA drives commercialization. The arrangement underscores Cipla’s strategy to expand its oncology-focused biosimilars portfolio and reduce cancer treatment costs for patients, following multiple collaborations with Chinese manufacturers.

+2

Derek Foss Patent cliff for Keytruda can't come soon enough. Hope this actually translates to lower prices once it hits the US market, not just corporate profit shifting.

IJREXCLUSIVE: Asst. Commerce Secretary Roth Reveals The Issues Facing Classrooms That Rely Too Much On ScreensSean Moran · 6 min · 1h